Is extending life by a few months worth $50,000? No, says the UK’s National Institute for Health and Clinical Excellence.
In a report out today, the group concluded that several new drugs for advanced kidney cancer aren’t cost-effective.
In the past few years, Pfizer’s Sutent, Wyeth’s Torisel, Nexavar from Onyx and Bayer and Avastin from Roche and [...]
Subscribe to:
Post Comments (Atom)
No comments:
Post a Comment